Welcome to our dedicated page for Helix Acqsn II SEC filings (Ticker: HLXB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with Helix Acquisition Corp. II (HLXB) document its formation and evolution from a healthcare-focused SPAC to the public company now known as BridgeBio Oncology Therapeutics, Inc. Investors can review the registration statements, current reports, and proxy materials that describe each step in this process.
Key filings include the IPO registration statement and related documents that detail the issuance of Class A ordinary shares, the trust account structure, and the rights of public shareholders. Current reports on Form 8-K provide official records of material events, such as the announcement and terms of the business combination with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), the effectiveness of the Form S-4 registration statement, and the results of the extraordinary general meeting at which shareholders approved the transaction and related proposals.
A Form 8-K filed after the August 11, 2025 closing describes the domestication of Helix from the Cayman Islands to Delaware, the merger of a Helix subsidiary with BBOT, the conversion of BBOT equity into shares and options of the public company, and the change of Helix’s name to BridgeBio Oncology Therapeutics, Inc. That filing also notes that the common stock of the renamed company is listed on the Nasdaq Global Market under the symbol BBOT, marking the transition from the HLXB SPAC ticker to the operating biopharmaceutical company.
Additional registration materials, such as the Form S-1 filed by BridgeBio Oncology Therapeutics, Inc. to register shares for resale by selling securityholders, further outline the post-combination capital structure and registration rights. On this page, Stock Titan surfaces these SEC documents and applies AI-powered summaries to help readers understand the purpose and main points of each filing, including business combination terms, share issuances, and changes in corporate structure linked to HLXB’s history.
BridgeBio Pharma entities disclosed ownership of 13,878,554 shares of BridgeBio Oncology Therapeutics, Inc. following the closing of a business combination on August 11, 2025. The shares consist of 13,805,126 common shares and options exercisable into 73,428 shares, representing approximately 17.5% of the 79,196,710 shares outstanding after the closing. The acquisition resulted from the merger between Helix Acquisition Corp. II and TheRas, Inc. under the Business Combination Agreement. Two BridgeBio directors, Neil Kumar and Frank P. McCormick, were appointed to the Issuer's board. The Reporting Persons state the shares were acquired for investment purposes and are subject to a one-year lock-up and registration rights.
Form 3 filing by Tipirneni Praveen P. reports initial beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (Ticker: BBOT). The filing, covering an event dated 08/11/2025, identifies the reporting person as a director and discloses two stock option awards exercisable for common stock. One option covers 81,069 shares with an exercise price of $5.18 and an exercisable date shown as 12/25/2034. The second option covers 4,855 shares with an exercise price of $7.88 and an exercisable date shown as 04/02/2035. The filing states each option vests in 1/48th monthly installments starting November 11, 2024 (first option) and April 4, 2025 (second option), subject to continuous service. The form is signed by an attorney-in-fact on 08/18/2025.
Michelle Doig, identified as a Director of BridgeBio Oncology Therapeutics, Inc. (BBOT), filed an initial Form 3 reporting a
Frank McCormick, a director of BridgeBio Oncology Therapeutics (BBOT), reported beneficial ownership consisting of two stock option awards. One option covers 141,870 shares exercisable in 2034 at $4.17 per share and a second option covers 8,497 shares exercisable in 2035 at $7.88 per share. Both awards vest monthly in equal installments as described in the filing. The Form 3 was submitted by one reporting person and includes a power of attorney.
BridgeBio Pharma LLC and its parent BridgeBio Pharma, Inc. reported an initial Form 3 disclosing 13,805,126 shares of common stock of BridgeBio Oncology Therapeutics, Inc. (BBOT) held indirectly. The filing shows two fully vested stock options covering 63,934 and 9,494 shares with exercise prices of $3.83 and $1.02, respectively. Voting and investment power is exercised by the parent, and the filers disclaim individual beneficial ownership except for any pecuniary interest.
Form 3 initial statement: Jake Bauer filed an initial Section 16 Form 3 reporting his relationship with BridgeBio Oncology Therapeutics (ticker BBOT) as a director. The filing states that no securities are beneficially owned by the reporting person and includes an Exhibit 24 power of attorney authorizing an attorney-in-fact to sign the form.
Kumar Neil is identified as a director of BridgeBio Oncology Therapeutics, Inc. (ticker: BBOT) on an initial Section 16 Form 3. The filing states that the reporting person does not beneficially own any securities of the issuer and references an executed power of attorney (Exhibit 24). The form reports the filing was made by one reporting person and is an initial statement of beneficial ownership.
Ben Yong filed an initial Form 3 reporting his beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (BBOT). The filing shows two stock options exercisable for common stock: 443,298 shares at an exercise price of $4.17 (exercisable 09/24/2034) and 26,551 shares at $7.88 (exercisable 04/02/2035). Vesting terms are stated: 25% of the larger option vests on September 3, 2025, with the remainder monthly over 36 months; the smaller option vests monthly in 48 equal installments beginning April 4, 2025. The form lists his role as Chief Medical & Development Officer and is signed by an attorney-in-fact on his behalf.
Wallace Eli M. filed an initial Form 3 reporting his beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (Ticker: BBOT). The filing shows two stock options: one for 620,618 shares of common stock exercisable beginning 07/22/2034 at an exercise price of $4.17, and one for 37,172 shares exercisable beginning 04/02/2035 at $7.88. The options vest monthly in 1/48th installments beginning May 1, 2024 and April 4, 2025 respectively, subject to continued service. The Form 3 indicates Wallace is both Chief Executive Officer and a Director. The filing was signed by an attorney-in-fact on 08/18/2025 and includes a Power of Attorney exhibit.
Mehra Uneek, serving as Chief Financial Officer and a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), filed an initial Form 3 reporting the event date